Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-09-02
DOI
10.3389/fimmu.2022.992611
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
- (2022) Sophie Cousin et al. EUROPEAN JOURNAL OF CANCER
- Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC).
- (2022) Afsaneh Barzi et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
- (2022) Ming Yi et al. Molecular Cancer
- A Tumor Microenvironments‐Adapted Polypeptide Hydrogel/Nanogel Composite Boosts Antitumor Molecularly Targeted Inhibition and Immunoactivation
- (2022) Zhongmin Li et al. ADVANCED MATERIALS
- Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma
- (2022) I-Tsang Chiang et al. BIOMEDICINE & PHARMACOTHERAPY
- Regorafenib induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation
- (2022) Mingjia Zhang et al. STEM CELLS AND DEVELOPMENT
- Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling
- (2022) Kevin Kos et al. OncoImmunology
- Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
- (2022) Jingjun Huang et al. Journal of Hepatocellular Carcinoma
- A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
- (2022) Richard D. Kim et al. EUROPEAN JOURNAL OF CANCER
- Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
- (2022) Benjamin H. Jenkins et al. PHARMACOLOGY & THERAPEUTICS
- Regorafenib-Avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE) : a single arm, open-label, phase II trial
- (2021) Sophie Cousin et al. CLINICAL CANCER RESEARCH
- Nivolumab plus regorafenib in patients with small bowel adenocarcinoma
- (2021) Gairong Zhang et al. MEDICINE
- Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment
- (2021) Hongzhen Bai et al. Nature Communications
- Tumor resident regulatory T cells
- (2021) Ariella Glasner et al. SEMINARS IN IMMUNOLOGY
- Roles of BTLA in Immunity and Immune Disorders
- (2021) Zhaochen Ning et al. Frontiers in Immunology
- Gastrointestinal stromal tumours
- (2021) Jean-Yves Blay et al. Nature Reviews Disease Primers
- Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
- (2021) Da-Liang Ou et al. Journal for ImmunoTherapy of Cancer
- β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression
- (2021) Daniel Hofbauer et al. IMMUNITY
- Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
- (2021) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).
- (2021) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
- (2021) Dennis Doleschel et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitors in melanoma
- (2021) Matteo S Carlino et al. LANCET
- Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment
- (2021) Alessandro Granito et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells
- (2021) Aya Takahashi et al. Frontiers in Oncology
- Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature
- (2021) Yong Zhang et al. BMC GASTROENTEROLOGY
- The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance
- (2021) Bikash Chandra Jena et al. CANCER LETTERS
- Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
- (2021) Shuangli Zhu et al. Experimental Hematology & Oncology
- Evolving role of regorafenib for the treatment of advanced cancers
- (2020) Axel Grothey et al. CANCER TREATMENT REVIEWS
- CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis
- (2020) Hui Yang et al. Molecular Cancer
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- The p38 Pathway: From Biology to Cancer Therapy
- (2020) Adrián Martínez-Limón et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis
- (2020) Xiao-Yong Huang et al. Molecular Cancer
- Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
- (2020) Constance J. Martin et al. Science Translational Medicine
- Natural killer cells in cancer biology and therapy
- (2020) Song-Yang Wu et al. Molecular Cancer
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib
- (2020) Alessandra Santangelo et al. NEURO-ONCOLOGY
- Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
- (2020) Qingyang Lei et al. Frontiers in Cell and Developmental Biology
- Chemokine biology on immune checkpoint–targeted therapies
- (2020) Diane Letourneur et al. EUROPEAN JOURNAL OF CANCER
- LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis
- (2020) Hao Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)
- (2020) Weijun Hong et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression
- (2020) Ori Maller et al. NATURE MATERIALS
- Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
- (2020) Er-lei Zhang et al. OncoTargets and Therapy
- Tumor microenvironment as a therapeutic target in cancer
- (2020) Yi Xiao et al. PHARMACOLOGY & THERAPEUTICS
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies
- (2019) Laura Hüser et al. Oncotarget
- Angiopoietin-2/Tie2 inhibition by regorafenib associates with striking response in a patient with aggressive hepatocellular carcinoma
- (2019) Paola Todesca et al. HEPATOLOGY
- Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
- (2019) Michael Teufel et al. GASTROENTEROLOGY
- Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
- (2019) Rui-Yan Wu et al. CLINICAL CANCER RESEARCH
- Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
- (2019) Ivan Perrot et al. Cell Reports
- Tumour-associated neutrophils in patients with cancer
- (2019) Merav E. Shaul et al. Nature Reviews Clinical Oncology
- UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
- (2019) Yochai Wolf et al. CELL
- Neoantigen vaccine: an emerging tumor immunotherapy
- (2019) Miao Peng et al. Molecular Cancer
- LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint
- (2019) Lina Zhao et al. Cell Death & Disease
- Molecular insight of regorafenib treatment for colorectal cancer
- (2019) Hiroyuki Arai et al. CANCER TREATMENT REVIEWS
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
- (2019) Li-Tzong Chen et al. Gastric Cancer
- Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
- (2018) Ana Costa et al. CANCER CELL
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- CD10 + GPR77 + Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness
- (2018) Shicheng Su et al. CELL
- Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells
- (2018) Jun Arai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- The dark side of tumor-associated endothelial cells
- (2018) Francesco De Sanctis et al. SEMINARS IN IMMUNOLOGY
- Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy
- (2018) Pengfei Zhao et al. Chemical Science
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade
- (2018) Hong Jae Chon et al. CLINICAL CANCER RESEARCH
- Tim-3 expression and its role in hepatocellular carcinoma
- (2018) Feifei Liu et al. Journal of Hematology & Oncology
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma
- (2018) Su Yeon Yeon et al. PATHOLOGY RESEARCH AND PRACTICE
- Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
- (2018) Hanne Locy et al. Frontiers in Immunology
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Foxp3-independent mechanism by which TGF-β controls peripheral T cell tolerance
- (2017) Soyoung A. Oh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
- (2017) Antje Sucker et al. Nature Communications
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Deletion of Na+/H+ exchanger regulatory factor 2 represses colon cancer progress by suppression of Stat3 and CD24
- (2016) Michihiro Yoshida et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- TGF Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
- (2016) D. R. Principe et al. CANCER RESEARCH
- Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
- (2016) Hidehiko Takigawa et al. CANCER SCIENCE
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
- (2016) Nick Pavlakis et al. JOURNAL OF CLINICAL ONCOLOGY
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival
- (2016) Jian-Fei Tu et al. Scientific Reports
- Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
- (2016) Jung-Chen Su et al. Scientific Reports
- Targeting CD73 in the tumor microenvironment with MEDI9447
- (2016) Carl M. Hay et al. OncoImmunology
- Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
- (2015) Elizabeth Buchbinder et al. JOURNAL OF CLINICAL INVESTIGATION
- Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
- (2015) Hung Huynh et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma
- (2015) Pei Zhang et al. JOURNAL OF SURGICAL RESEARCH
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- MICA polymorphism: biology and importance in cancer
- (2014) D. Chen et al. CARCINOGENESIS
- STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
- (2014) W.-T. Tai et al. CLINICAL CANCER RESEARCH
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
- (2014) A. Young et al. Cancer Discovery
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
- (2013) L. Abou-Elkacem et al. MOLECULAR CANCER THERAPEUTICS
- Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
- (2013) Andrew L Doedens et al. NATURE IMMUNOLOGY
- Molecular Pathways: Targeting the TGF- Pathway for Cancer Therapy
- (2012) A. L. Smith et al. CLINICAL CANCER RESEARCH
- Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progression
- (2012) Zhaoyang Li et al. INTERNATIONAL JOURNAL OF CANCER
- The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner
- (2012) Yong Yi et al. JOURNAL OF HEPATOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation
- (2011) Terence Kin Wah Lee et al. Cell Stem Cell
- Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
- (2011) H. Huang et al. CLINICAL CANCER RESEARCH
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery
- (2009) X.-R. Yang et al. CLINICAL CANCER RESEARCH
- Tumor-Associated MICA Is Shed by ADAM Proteases
- (2008) I. Waldhauer et al. CANCER RESEARCH
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Modulation of the antitumor immune response by complement
- (2008) Maciej M Markiewski et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now